Full-Time

Senior Electrical Engineer

Glaukos

Glaukos

1,001-5,000 employees

Medical devices for glaucoma treatment

Compensation Overview

$97.9k - $122.4k/yr

Burlington, MA, USA

In Person

Category
Electrical Engineering
Required Skills
Printed Circuit Board (PCB) Design
Altium
PSpice
OrCAD
MATLAB
Simulink
LTSpice

Get referred to Glaukos

See people who can refer or advise you

Requirements
  • Bachelor’s or Master’s degree in Electrical Engineering or a related field
  • 5+ years of progressive experience in electrical engineering, including complex PCB and system-level design
  • Strong knowledge of analog, digital, mixed-signal, and power circuit design, validated by advanced circuit simulation, modeling, and analysis
  • Hands-on experience with EDA and simulation tools, including PSpice, LTspice, MATLAB/Simulink, Altium Designer (preferred), Allegro PCB, and ORCAD
  • Proven experience in signal integrity, power integrity, EMC/EMI, and thermal simulations for complex electronic systems
  • Strong background in motor control circuits, sensors, and communication interfaces, including I2C, SPI, UART, CAN, Wi-Fi, and BLE
  • Demonstrated experience defining and executing design verification and validation protocols under FDA design control requirements
  • Working experience within a QMS/ISO13485
  • Familiarity with IEC 60601-1, IEC 60601-1-2, and other applicable electrical safety and EMC standards
  • Excellent analytical, problem-solving, and cross-functional collaboration skills
Responsibilities
  • Execute detailed circuit design for analog, digital, mixed-signal, and power electronics
  • Perform schematic capture, complex multi-layer PCB layout, and board bring-up testing
  • Perform advanced circuit simulations, including DC, AC, transient, Monte Carlo, noise, signal integrity, power integrity, and EMC/EMI modeling
  • Conduct worst-case, tolerance, and reliability analyses to anticipate failure modes and ensure long-term product robustness
  • Drive thermal and power distribution modeling to inform PCB layout strategies
  • Support the selection, evaluation, and integration of off-the-shelf electrical components such as displays, power supplies, SBCs, motors, and sensors
  • Develop and maintain detailed electrical wiring diagrams aligned with system-level architecture and direction from the engineering manager
  • Manage CAD tools and ensure robust configuration management of the PCB design environment
  • Maintain and update Altium tool settings, templates, design rules, and standardized workflows
  • Manage and control the electronic component library, including symbols, footprints, 3D models, and component parameters
  • Ensure traceability, revision control, and compliance with QMS and design control documentation requirements
  • Support prototype builds, board bring-up, debugging, and root-cause analysis of hardware issues
  • Design and document PCBA and assembly test fixtures to support development and verification testing
  • Collaborate closely with software and firmware teams to ensure successful hardware–firmware integration
  • Support system-level integration and troubleshooting across electrical, mechanical, and software domains
  • Define system level test protocols for system integration evaluation
  • Define, document, and execute electrical design verification and validation protocols for assigned boards and subsystems
  • Generate and maintain design documentation, test reports, and technical justifications in accordance with FDA design controls and QMS requirements
  • Support sustaining engineering activities including ECO implementation, component obsolescence management, and CAPA investigations
  • Provide technical support for manufacturing, supplier issues, and field feedback
  • Support compliance engineering activities for product safety and EMC testing, including IEC 60601-1, IEC 60601-1-2, and other applicable standards

Glaukos focuses on ophthalmology by developing and commercializing medical devices and therapies for glaucoma, corneal disorders, and retinal diseases. Its products mainly target surgeons who treat eye conditions, with a core technology in micro invasive glaucoma surgery (MIGS). The company’s MIGS devices, such as the Trabecular Micro Bypass Stent and next-generation iStent, are implanted in the eye to improve outflow of eye fluid and lower intraocular pressure, offering a less invasive option compared with traditional surgeries. Glaukos differentiates itself by pioneering MIGS and bringing the first US-approved MIGS device to market in 2012, continuing to expand its portfolio through research, development, and strategic acquisitions. The company aims to improve patient care by providing safer, effective, and longer-lasting treatment options for glaucoma and related eye diseases, addressing unmet needs in ophthalmology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Aliso Viejo, California

Founded

1998

Get referred to Glaukos

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Glaukos reported record Q1 2026 glaucoma net sales of $129.3 million, up 47% year-over-year[2].
  • Permanent J-code J2789 effective July 1, 2026 streamlines reimbursement and expands payer coverage for Epioxa[1].
  • Orsini Specialty Pharmacy serves as single-source partner to accelerate rare disease patient access for Epioxa[2].

What critics are saying

  • Major insurers like Aetna exclude Epioxa coverage due to 'experimental' status, risking near-zero adoption[2].
  • $78,500 wholesale cost is 3–5× higher than traditional CXL, triggering severe payer resistance and denials[2].
  • Discontinuing Photrexa in 2026 creates a cash gap amid $187.7M operating losses without guaranteed Epioxa uptake[2].

What makes Glaukos unique

  • Glaukos pioneered MIGS and launched the first US-approved MIGS device in 2012[1].
  • Epioxa is the only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus[2].
  • Epioxa uses oxygen-enriched, UV-activated topical formulation without epithelium removal[2].

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Women In Optometry
Apr 17th, 2026
Glaukos receives permanent J-code for Epioxa(TM).

Glaukos receives permanent J-code for Epioxa(TM). New J-code for Epioxa(TM), J2789, set to become effective July 1, 2026. April 17, 2026 Glaukos Corporation announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa(TM) HD/Epioxa(TM)("Epioxa") for the treatment of keratoconus. ABOUT the code. The new J-code for Epioxa, J2789, is set to become effective July 1, 2026. It is expected to streamline the reporting and payment of Epioxa by U.S. payers over time. "The assignment of a product-specific J-code for Epioxa represents an important milestone, supporting our market access initiatives to increase access and expand coverage for patients suffering from keratoconus," said Thomas Burns, Glaukos chairman and chief executive officer. "Once effective, this new J-code is expected to enable more streamlined and consistent coverage and payment for Epioxa over time, strengthening the foundation for our commercial launch and enabling broader patient access." J-codes are reported by U.S. health care providers and used by U.S. government and commercial payers to streamline the billing and reimbursement process for pharmaceuticals, such as Epioxa, administered by a health care professional. Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to eliminate the pain associated with removal of the epithelium, streamline the procedure and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers and the health care system. ABOUT EPIOXA HD/EPIOXA Indication: EPIOXA(TM) HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA(TM)(riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n(TM) System and the Boost Goggles(R). Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator's Manual and Boost Goggles User Guide for device instructions. Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens. Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis. Adverse Reactions: The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.